A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
This research study is looking for adults with early, seropositive rheumatoid arthritis to compare two treatments: abatacept and adalimumab. Participants will already be taking methotrexate, but their arthritis hasn't improved enough. The study aims to find out if one of these medications is more effective than the other at controlling rheumatoid arthritis symptoms and improving how participants feel overall. Doctors hope to learn which treatment works best for specific patients with more advanced signs of the condition, helping more people get better relief from their symptoms and live fuller lives. It's a late-stage clinical trial, meaning the medications have already been tested for safety in earlier studies.
Auf einen Blick
Ergebnisse
Ergebnisse dieser Studie
Veröffentlicht October 2024Die Ergebnisse dieser Studie wurden veröffentlicht.
Worum geht es in dieser Studie?
Rheumatoid arthritis (RA) is a long-term condition that causes pain, swelling, and stiffness in the joints. It happens when the body's immune system, which normally fights off infections, mistakenly attacks the lining of the joints. This can lead to joint damage and affect daily activities. Finding the right treatment early can help manage symptoms and prevent further damage.
This study is designed for people who have been recently diagnosed with rheumatoid arthritis – specifically, those with a type known as 'seropositive' and 'shared epitope-positive' RA, which means certain markers show in their blood tests that can indicate more aggressive disease. These patients have also tried methotrexate, a common RA medication, but it hasn't worked well enough to control their symptoms. The researchers want to compare two other advanced medications, abatacept and adalimumab, to see which one might be more effective for this specific group of patients.
The main goal is to find out if abatacept works better than adalimumab in reducing the signs and symptoms of rheumatoid arthritis. Both of these are 'biologic' medicines, which target specific parts of the immune system involved in RA. By finding out which treatment is superior, doctors can make more informed decisions about how to best help people with early, active rheumatoid arthritis to achieve better symptom control and improve their quality of life.
Wichtige Erkenntnisse
- This study compares two advanced treatments (abatacept and adalimumab) for rheumatoid arthritis.
- It's for adults whose early RA hasn't improved enough with methotrexate.
- Participants have a specific type of RA that can be more active.
- The goal is to find out which treatment works better for these patients.
- You'll receive close medical care and regular check-ups during the study.
Wer könnte berechtigt sein?
This study is looking for adults aged 18 and over who have been recently diagnosed with rheumatoid arthritis, meaning your symptoms started within the last year. You must have already been taking methotrexate for at least 3 months, at a steady dose for the last month, but your arthritis is still active and not well-controlled. Your blood tests must also show specific markers for rheumatoid arthritis, suggesting a more severe form of the condition. You will also need to have a certain number of tender and swollen joints, and your doctor will use a specific score (DAS28-CRP) to confirm your arthritis is active enough to join.
There are several reasons why you might not be able to join. For example, if you are pregnant or breastfeeding, or if you have other autoimmune conditions like psoriasis or lupus. You also can't participate if you've already tried other 'biologic' or similar advanced arthritis medications. The study also cannot include anyone who has had certain infections, such as tuberculosis, or who has a weakened immune system, as these medications can affect your immune response. You also cannot have certain other conditions that might interfere with the study's safety or results.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Were your RA symptoms diagnosed within the last 12 months?
- Have you been taking methotrexate for at least 3 months, and for a steady dose for the last month?
- Are your rheumatoid arthritis symptoms still active despite methotrexate?
- Do your blood tests show specific markers for rheumatoid arthritis (seropositive)?
- Are you currently not pregnant or breastfeeding, and do not have certain other serious health conditions or infections?
Was beinhaltet die Teilnahme?
If you decide to take part, you will be given either abatacept or adalimumab, in addition to your current methotrexate. You won't know which of the two study drugs you are receiving, nor will your study doctor, which helps keep the study fair and unbiased. Your participation will involve regular visits to the clinic for medical check-ups, blood tests, and assessments of your joints to see how your arthritis is responding to treatment. You'll also be asked about your symptoms and how you're feeling. The study will last for a specific period, and detailed information about the time commitment and schedule of visits will be provided to you by the study team. You'll continue to receive regular medical care throughout the study.
Potenzielle Risiken und Vorteile
Locations (75)
- Local Institution - 0036Verifizierte PostleitzahlFullerton, Vereinigte Staaten
- Local Institution - 0086Verifizierte PostleitzahlLos Alamitos, Vereinigte Staaten
- Local Institution - 0041Verifizierte PostleitzahlAurora, Vereinigte Staaten
- Local Institution - 0058Verifizierte PostleitzahlCumberland, United States
- Local Institution - 0038Verifizierte PostleitzahlHagerstown, United States
- Local Institution - 0084Verifizierte PostleitzahlEagan, United States
- Local Institution - 0040Verifizierte PostleitzahlFreehold, United States
- NYU Langone Ambulatory Care Brooklyn HeightsVerifizierte PostleitzahlBrooklyn, United States
- Local Institution - 0082Verifizierte PostleitzahlWilmington, Vereinigte Staaten
- Local Institution - 0127Verifizierte PostleitzahlPortland, Vereinigte Staaten
- Local Institution - 0031Verifizierte PostleitzahlDuncansville, United States
- Local Institution - 0034Verifizierte PostleitzahlJackson, United States
Häufige Fragen
What is 'seropositive' rheumatoid arthritis?
This means blood tests show specific markers (like rheumatoid factor and anti-CCP antibodies) which confirm rheumatoid arthritis and can sometimes mean a more active form of the disease.
What is methotrexate?
Methotrexate is a common medication used to reduce inflammation and slow down the progression of rheumatoid arthritis. It's often one of the first treatments doctors try.
What does a 'Phase 3' study mean?
Phase 3 means these medications have already been tested in earlier studies for safety and some effectiveness. This phase compares them to existing treatments or other new treatments in a larger group of people to confirm their benefits and check for any less common side effects.
Werde ich wissen, welche Behandlung ich bekomme?
No, in this type of study, neither you nor your study doctor will know whether you are receiving abatacept or adalimumab. This helps ensure the results are unbiased and reliable.
Wie lange wird die Studie dauern?
The exact duration for each participant will be explained by the study team, but clinical trials usually involve a commitment over several months or even a couple of years, with regular clinic visits.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.